Meningococcal Vaccine Approved for Kids & Infants – FDA
- The Food and drug Management has broadened its approval of the MenQuadfi meningococcal vaccine, manufactured by Sanofi Pasteur Inc., to include infants as young as 6 weeks old.
- MenQuadfi is administered as an intramuscular injection to provide active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.These bacteria can lead to...
- For infants starting at 6 weeks, the vaccination schedule involves a 4-dose series given at 2, 4, 6, and between 12 and 18 months.
The FDA has greenlit MenQuadfi, a meningococcal vaccine, for infants as young as 6 weeks old, marking a significant step in safeguarding children against invasive meningococcal disease. This crucial primary_keyword protects against severe infections like meningitis and bloodstream infections, offering a 4-dose or 2-dose series based on age. This secondary_keyword aims to broaden access to protection for vulnerable young ones. news Directory 3 brings you the latest on this vital health update. Learn about the vaccine’s schedule, the severe nature of the infection, and the potential for reducing the impact of this perilous disease. Discover what’s next for this expanded approval, and if it’s right for you and your child.
FDA Approves MenQuadfi Vaccine for Infants, Expanding Meningococcal Disease Protection
Updated May 29, 2025
The Food and drug Management has broadened its approval of the MenQuadfi meningococcal vaccine, manufactured by Sanofi Pasteur Inc., to include infants as young as 6 weeks old. This expansion aims to prevent invasive meningococcal disease in children aged 6 weeks to 23 months.
Image credit: Alexey Novikov | stock.adobe.com
MenQuadfi is administered as an intramuscular injection to provide active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.These bacteria can lead to severe infections, including meningitis and bloodstream infections.
For infants starting at 6 weeks, the vaccination schedule involves a 4-dose series given at 2, 4, 6, and between 12 and 18 months. Infants between 6 and 23 months can also receive a 2-dose series, with the second dose administered at least 3 months after the first, during the child’s second year.
Meningococcal infections spread through respiratory and throat secretions during close contact. Meningitis, one of the most common infections, causes swelling of the brain and spinal cord lining. Bloodstream infections can lead to bleeding in the skin and organs. Symptoms vary, but infants may exhibit vomiting, irritability, and poor feeding.
“Meningococcal meningitis remains a major global health challenge as it can strike quickly and with devastating affect, taking a life in less than 24 hours,” said David Loew, executive vice president of Sanofi Pasteur.
MenQuadfi stands out as the first quadrivalent meningococcal vaccine in the U.S.to utilize tetanus toxoid as a protein carrier. it is also the only FDA-approved quadrivalent vaccine for individuals aged 2 through 56 years.
The initial FDA approval in April 2020 was based on data from multiple trials involving nearly 5,000 participants aged 2 and older. These studies demonstrated the vaccine’s safety and effectiveness in generating immune responses comparable to other licensed vaccines. Common side effects include injection site pain, muscle ache, headache, and fatigue.
What’s next
with this expanded approval, wider access to the meningococcal vaccine is anticipated, possibly reducing the incidence of invasive meningococcal disease among young children. Parents should consult with their pediatricians about the appropriate timing for MenQuadfi vaccination.